First In Class Logic Gated Allogeneic CAR Cell Therapy with RMAT Designation Phase 1 Data

• Demonstrating clinical outcomes from phase 1 trials
• Exploring predictive biomarkers to optimize response, safety and trial design in allogeneic therapies
• Showcasing how clinical data enabled regulatory progress and informed pivotal study strategies

Speakers:

Kanya Rajangam

President, Chief Medical Officer & Head of Research & Development

Senti Biosciences Inc.